Skip to main content
. 2003 Jul;133(1):132–138. doi: 10.1046/j.1365-2249.2003.02192.x

Fig. 2.

Fig. 2

Expression profile of inflammatory cytokine and receptor genes in PBMC from RA patients before (week 0) and after (week 24) leflunomide and MTX treatment detected by cDNA expression array system. Total RNA was extracted from PBMC, reverse-transcribed and labelled with biotin, and gene expressions were detected using the GEArray™ Q series Kit. Genes with differential expressions in RA patients upon combination treatment were indicated by number-labelled boxes: MCP-1 (1), TARC (2), MDC (3), MPIF-1 (4), I-309 (5), IL-15 (6), CCR2 (7), CCR4 (8), TECK (9) and MIP-1 beta (10). Negative control genes: pUC18 DNA (13 A, 13B, 13C); positive control (housekeeping) genes: GAPDH (13G, 13H), cyclophilin A (14 A, 14B, 14C, 14D), ribosomal protein L13A (RPL13A) (14E, 14F), β-actin (14G, 14H).